Nebivolol for the treatment of heart failure

Expert Opinion on Investigational Drugs

Volumn 20, Issue 12, 2011, Pages 1733-1746

  Riva, Nicoletta ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

blockers; Heart failure; Nebivolol

Indexed keywords

DIGOXIN; FUROSEMIDE; HYDROCHLOROTHIAZIDE; LOSARTAN; NEBIVOLOL; PLACEBO; RAMIPRIL; RANITIDINE; WARFARIN;

ARTICLE; BRADYCARDIA; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPNEA; EDEMA; ERECTILE DYSFUNCTION; FATIGUE; HEADACHE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION TIME; HOSPITAL ADMISSION; HUMAN; INSULIN RESISTANCE; LIPOPHILICITY; MORTALITY; NAUSEA; NONHUMAN; PARESTHESIA; SIDE EFFECT;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; BENZOPYRANS; CLINICAL TRIALS AS TOPIC; ETHANOLAMINES; HEART FAILURE; HUMANS; SYMPATHETIC NERVOUS SYSTEM;

EID: 81555208938     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2011.625011     Document Type: Article

References (89)

1. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;20:e391-479.
2. Barker WH, Mullooly JP, Getchell W. Changing incidence and survival for heart failure in a well-defined older population, 1970-1974 and 1990-1994. Circulation 2006;113:799-805
3. Mosterd A, Hoes AW, de Bruyne MC, et al. Prevalence of heart failure and left ventricular dysfunction in the general population; the Rotterdam study. Eur Heart J 1999;20:447-55 (Pubitemid 29116541)
4. Triposkiadis F, Karayannis G, Giamouzis G, et al. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J Am Coll Cardiol 2009;54:1747-62.
5. Longhini C, Molino C, Fabbian F. Cardiorenal syndrome: still not a defined entity. Clin Exp Nephrol 2010;14:12-21
6. Grassi G, Seravalle G, Quarti-Trevano F. The 'neuroadrenergic hypothesis' in hypertension: current evidence. Exp Physiol 2010;95:581-6
7. Ursino MG, Vasina V, Raschi E, et al. The beta3-adrenoceptor as a therapeutic target: current perspectives. Pharmacol Res 2009;59:221-34
8. Gauthier C, Seze-Goismier C, Rozec B. Beta 3-adrenoceptors in the cardiovascular system. Clin Hemorheol Microcirc 2007;37:193-204 (Pubitemid 47015825)
9. Satwani S, Dec GW, Narula J. Beta-adrenergic blockers in heart failure: review of mechanisms of action and clinical outcomes. J Cardiovasc Pharmacol Ther 2004;9:243-55 (Pubitemid 40130011)
10. The Cardiac Insufficiency Bisoprolol Study. II (CIBIS-II): a randomised trial. Lancet 1999;353:9-13
11. Hjalmarson A, Goldstein S, Fagerberg B, et al. for the MERIT-HF Study Group. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). JAMA 2000;283:1295-302 (Pubitemid 30129796)
12. Packer M, Fowler MB, Roecker EB, et al. for the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 2002;106:2194-9 (Pubitemid 35222212)
13. Poole-Wilson PA, Swedberg K, Cleland JG, et al. for the COMET investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003;362:7-13 (Pubitemid 36835815)
14. Beta-Blocker Evaluation of Survival Trial Investigators. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001;344:1659-67
15. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008;29:2388-442.
16. Pauwels PJ, Gommeren W, Van Lommen G, et al. The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various beta-adrenergic blockers. Mol Pharmacol 1988;34:843-51 (Pubitemid 19014407)
17. Van Nueten L, De Cree J. Nebivolol: comparison of the effects of dl-nebivolol, d-nebivolol, l-nebivolol, atenolol, and placebo on exercise-induced increases in heart rate and systolic blood pressure. Cardiovasc Drugs Ther 1998;12:339-44 (Pubitemid 28479165)
18. Brixius K, Bundkirchen A, Bolck B, et al. Nebivolol, bucindolol, metoprolol and carvedilol are devoid of intrinsic sympathomimetic activity in human myocardium. Br J Pharmacol 2001;133:1330-8 (Pubitemid 32783494)
19. Bundkirchen A, Brixius K, Bolck B, et al. Beta 1-adrenoceptor selectivity of nebivolol and bisoprolol. A comparison of [3H]CGP 12.177 and [125I] iodocyanopindolol binding studies. Eur J Pharmacol 2003;460:19-26 (Pubitemid 36078480)
20. Cockcroft JR, Chowienczyk PJ, Brett SE, et al. Nebivolol vasodilates human forearm vasculature: evidence for an Larginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995;274:1067-71
21. Bowman AJ, Chen CP, Ford GA. Nitric oxide mediated venodilator effects of nebivolol. Br J Clin Pharmacol 1994;38:199-204 (Pubitemid 24282739)
22. Dessy C, Saliez J, Ghisdal P, et al. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation betablocker nebivolol. Circulation 2005;112:1198-205 (Pubitemid 41216127)
23. Broeders MA, Doevendans PA, Bekkers BC, et al. Nebivolol: a third-generation beta-blocker that augments vascular nitric oxide release: endothelial beta(2)-adrenergic receptor-mediated nitric oxide production. Circulation 2000;102:677-84 (Pubitemid 30640669)
24. Evangelista S, Garbin U, Pasini AF, et al. Effect of DL-nebivolol, its enantiomers and metabolites on the intracellular production of superoxide and nitric oxide in human endothelial cells. Pharmacol Res 2007;55:303-9 (Pubitemid 46533933)
25. de Groot AA, Mathy MJ, van Zwieten PA, Peters SL. Antioxidant activity of nebivolol in the rat aorta. J Cardiovasc Pharmacol 2004;43:148-53 (Pubitemid 38032077)
26. Sharma R, Davidoff MN. Oxidative stress and endothelial dysfunction in heart failure. Congest Heart Fail 2002;8:165-72 (Pubitemid 34665627)
27. Van de Water A, Janssens W, Van Neuten J, et al. Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist. J Cardiovasc Pharmacol 1988;11:552-63
28. Paulus WJ, Shah AM. NO and cardiac diastolic function. Cardiovasc Res 1999;43:595-606 (Pubitemid 29369258)
29. Brehm BR, Wolf SC, Bertsch D, et al. Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc Res 2001;49:430-9 (Pubitemid 32119560)
30. Wolf SC, Sauter G, Preyer M, et al. Influence of nebivolol and metoprolol on inflammatory mediators in human coronary endothelial or smooth muscle cells. Effects on neointima formation after balloon denudation in carotid arteries of rats treated with nebivolol. Cell Physiol Biochem 2007;19:129-36
31. Wolf SC, Sauter G, Jobst J, et al. Major differences in gene expression in human coronary smooth muscle cells after nebivolol or metoprolol treatment. Int J Cardiol 2008;125:4-10 (Pubitemid 351305421)
32. Kuroedov A, Cosentino F, Luscher TF. Pharmacological mechanisms of clinically favorable properties of a selective beta1-adrenoceptor antagonist, nebivolol. Cardiovasc Drug Rev 2004;22:155-68 (Pubitemid 39391186)
33. Falciani M, Rinaldi B, D'Agostino B, et al. Effects of nebivolol on human platelet aggregation. J Cardiovasc Pharmacol 2001;38:922-9 (Pubitemid 33104703)
34. Celik T, Yuksel UC, Iyisoy A, et al. Effects of nebivolol on platelet activation in hypertensive patients: a comparative study with metoprolol. Int J Cardiol 2007;116:206-11 (Pubitemid 46241480)
35. Van Peer A, Snoeck E, Woestenborghs R, et al. Clinical pharmacokinetics of nebivolol. A review. Drug Investig 1991;3:25-30
36. Mangrella M, Rossi F, Fici F, Rossi F. Pharmacology of nebivolol. Pharmacol Res 1998;38:419-31 (Pubitemid 29002262)
37. Gu Z, Robinson RA, Cai L, et al. Metabolism study of 14C-nebivolol in humans with different CYP2D6 genotypes. Paper presented at: American Association of Pharmaceutical Scientists Annual Meeting and Exposition; 26-30 October 2003; Salt Lake City, UT
38. Lefebvre J, Poirier L, Poirier P, et al. The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertension. Br J Clin Pharmacol 2007;63:575-82 (Pubitemid 46632567)
39. Cheymol G, Woestenborghs R, Snoeck E, et al. Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. Eur J Clin Pharmacol 1997;51:493-8 (Pubitemid 27317789)
40. Shaw AA, Liu S, Tu HC, et al. Effects of hepatic impairment on the pharmacokinetic disposition of nebivolol: a dual acting nitric oxide modulating/cardioselective beta1-antagonist. Clin Pharmacol Ther 2005;77:P41
41. Shaw AA, Liu S, Zachwieja LF, et al. Effects of varying degrees of renal impairment on the pharmacokinetic disposition of nebivolol. Clin Pharmacol Ther 2005;77:P38
42. Kamali F, Howes A, Thomas SH, et al. A pharmacokinetic and pharmacodynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidine. Br J Clin Pharmacol 1997;43:201-4 (Pubitemid 27085374)
43. Lindamood C, Ortiz S, Shaw A, et al. Effects of commonly administered agents and genetics on nebivolol pharmacokinetics: drug-drug interaction studies. J Clin Pharmacol 2011;51:575-85
44. A.Menarini Pharmaceuticals UK. Nebilet 5 mg tablets: summary of product characteristics. Available from: http://www.medicines.org.uk/EMC/medicine/9145/ SPC/Nebilet+5mg+Tablets/[Last accessed 10 September 2011].
45. Bystolic (nebivolol) tablets: prescribing information. Available from: http://www. frx.com/pi/bystolic-pi.pdf [Last accessed 12 September 2011].
46. Cazzola M, Matera MG, Ruggeri P, et al. Comparative effects of a two-week treatment with nebivolol and nifedipine in hypertensive patients suffering from COPD. Respiration 2004;71:159-64 (Pubitemid 38529171)
47. Cheng JW. Nebivolol: a third-generation beta-blocker for hypertension. Clin Ther 2009;31:447-62
48. Brixius K, Middeke M, Lichtenthal A, et al. Nitric oxide, erectile dysfunction and beta-blocker treatment (MR NOED study): benefit of nebivolol versus metoprolol in hypertensive men. Clin Exp Pharmacol Physiol 2007;34:327-31
49. Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? Am J Hypertens 1998;11:1258-65
50. Pischon T, Sharma AM. Use of beta-blockers in obesity hypertension: potential role of weight gain. Obes Rev 2001;2:275-80 (Pubitemid 33755903)
51. Agabiti Rosei E, Rizzoni D. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics. Drugs 2007;67:1097-107 (Pubitemid 46871021)
52. Gielen W, Cleophas TJ, Agrawal R. Nebivolol: a review of its clinical and pharmacological characteristics. Int J Clin Pharmacol Ther 2006;44:344-57 (Pubitemid 44210009)
53. De Cree J, Geukens H, Cobo C, Verhaegen H. Subacute hemodynamic effects of nebivolol in man at rest and during exercise. Angiology 1987;38:440-8 (Pubitemid 17101763)
54. De Cree J, Franken P, Vandevivere J, et al. Hemodynamic effects of nebivolol in men: comparison of radionuclide angiocardiography with systolic time intervals. Angiology 1988;39:526-34
55. De Cree J, Cobo C, Geukens H, Verhaegen H. Comparison of the subacute hemodynamic effects of atenolol, propranolol, pindolol, and nebivolol. Angiology 1990;41:95-105 (Pubitemid 20085266)
56. De Cree J, Van Nueten L, Geukens H, Verhaegen H. Comparative cardiac haemodynamics of bisoprolol, celiprolol, carvedilol and nebivolol in normal volunteers. Int J Clin Pharmacol Res 1992;12:159-63 (Pubitemid 23117489)
57. Brune S, Schmidt T, Tebbe U, Kreuzer H. Hemodynamic effects of nebivolol at rest and on exertion in patients with heart failure. Angiology 1990;41:696-701 (Pubitemid 20357088)
58. Lechat P, Boutelant S, Komajda M, et al. Pilot study of cardiovascular effects of nebivolol in congestive heart failure. Drug Investig 1991;3:69-81
59. Wisenbaugh T, Katz I, Davis J, et al. Long-term (3-month) effects of a new beta-blocker (nebivolol) on cardiac performance in dilated cardiomyopathy. J Am Coll Cardiol 1993;21:1094-100 (Pubitemid 23106181)
60. Uhlir O, Dvorak I, Gregor P, et al. Nebivolol in the treatment of cardiac failure: a double-blind controlled clinical trial. J Card Fail 1997;3:271-6 (Pubitemid 127674859)
61. Brehm BR, Wolf SC, Gorner S, et al. Effect of nebivolol on left ventricular function in patients with chronic heart failure: a pilot study. Eur J Heart Fail 2002;4:757-63 (Pubitemid 35403085)
62. Patrianakos AP, Parthenakis FI, Mavrakis HE, et al. Effects of Nebivolol on left ventricular function and exercise capacity in patients with non-ischaemic dilated cardiomyopathy. A randomised placebo-controlled study. Hellenic J Cardiol 2005;46:199-207 (Pubitemid 41664055)
63. Erdogan D, Gullu H, Caliskan M, et al. Nebivolol improves coronary flow reserve in patients with idiopathic dilated cardiomyopathy. Heart 2007;93:319-24 (Pubitemid 46579520)
64. Edes I, Gasior Z, Wita K. Effects of nebivolol on left ventricular function in elderly patients with chronic heart failure: results of the ENECA study. Eur J Heart Fail 2005;7:631-9 (Pubitemid 40732997)
65. Rousseau MF, Chapelle F, Van Eyll C, et al. Medium-term effects of beta-blockade on left ventricular mechanics: a double-blind, placebo-controlled comparison of nebivolol and atenolol in patients with ischemic left ventricular dysfunction. J Card Fail 1996;2:15-23 (Pubitemid 126666350)
66. Nodari S, Metra M, Dei Cas L. Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol. Eur J Heart Fail 2003;5:621-7 (Pubitemid 38043967)
67. Patrianakos AP, Parthenakis FI, Mavrakis HE, et al. Comparative efficacy of nebivolol versus carvedilol on left ventricular function and exercise capacity in patients with nonischemic dilated cardiomyopathy. A 12-month study. Am Heart J 2005;150:985-e9-18
68. Lombardo RM, Reina C, Abrignani MG, et al. Effects of nebivolol versus carvedilol on left ventricular function in patients with chronic heart failure and reduced left ventricular systolic function. Am J Cardiovasc Drugs 2006;6:259-63 (Pubitemid 44285135)
69. Marazzi G, Volterrani M, Caminiti G, et al. Comparative long term effects of nebivolol and carvedilol in hypertensive heart failure patients. J Card Fail 2011;17:703-9
70. Flather MD, Shibata MC, Coats AJ, et al. on behalf of the SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005;26:215-25 (Pubitemid 40222359)
71. Shibata MC, Flather MD, Wang D. Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure. Eur J Heart Fail 2001;3:351-7 (Pubitemid 32895844)
72. Nasr IA, Bouzamondo A, Hulot JS, et al. Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. Eur Heart J 2007;28:457-62 (Pubitemid 47343566)
73. Ghio S, Magrini G, Serio A, et al. on behalf of the SENIORS investigators. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. Eur Heart J 2006;27:562-8
74. van Veldhuisen DJ, Cohen-Solal A, Bohm M, et al. on behalf of the SENIORS Investigators. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol 2009;53:2150-8
75. Ambrosio G, Flather MD, Bohm M, et al. beta-blockade with nebivolol for prevention of acute ischaemic events in elderly patients with heart failure. Heart 2011;97:209-14
76. Bolli R. Cardioprotective function of inducible nitric oxide synthase and role of nitric oxide in myocardial ischemia and preconditioning: an overview of a decade of research. J Mol Cell Cardiol 2001;33:1897-918 (Pubitemid 33097270)
77. Dobre D, van Veldhuisen DJ, Mordenti G, et al. on behalf of the SENIORS Investigators. Tolerability and dose-related effects of nebivolol in elderly patients with heart failure: data from the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS) trial. Am Heart J 2007;154:109-15 (Pubitemid 46920477)
78. Cohen-Solal A, Kotecha D, van Veldhuisen DJ, et al. on behalf of the SENIORS Investigators. Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial. Eur J Heart Fail 2009;11:872-80
79. de Boer RA, Doehner W, van der Horst IC, et al. on behalf of the SENIORS Investigators. Influence of diabetes mellitus and hyperglycemia on prognosis in patients > or =70 years old with heart failure and effects of nebivolol (data from the Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with heart failure [SENIORS]). Am J Cardiol 2010;106:78-86; e1
80. Cai L, Kang YJ. Oxidative stress and diabetic cardiomyopathy: a brief review. Cardiovasc Toxicol 2001;1:181-93 (Pubitemid 37013746)
81. Palazzuoli A, Antonelli G, Nuti R. Anemia in Cardio-Renal Syndrome: clinical impact and pathophysiologic mechanisms. Heart Fail Rev 2011;16:603-7
82. von Haehling S, van Veldhuisen DJ, Roughton M, et al. Anaemia among patients with heart failure and preserved or reduced ejection fraction: results from the SENIORS study. Eur J Heart Fail 2011;13:656-63
83. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-536
84. Predel HG, Mainka W, Schillings W, et al. Integrated effects of the vasodilating beta-blocker nebivolol on exercise performance, energy metabolism, cardiovascular and neurohormonal parameters in physically active patients with arterial hypertension. J Hum Hypertens 2001;15:715-21 (Pubitemid 32975871)
85. Food and Drug Administration. Meeting of the Cardiovascular and Renal Drugs Advisory Committee. Available from: http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ CardiovascularandRenalDrugsAdvisory Committee/UCM199554.pdf [Last accessed 9 July 2011]
86. Dulin BR, Haas SJ, Abraham WT, Krum H. Do elderly systolic heart failure patients benefit from beta blockers to the same extent as the non-elderly? Meta-analysis of >12,000 patients in large-scale clinical trials. Am J Cardiol 2005;95:896-8 (Pubitemid 40386810)
87. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006;355:260-9 (Pubitemid 44088349)
88. Hermans MP, De Coster O, Seidel L, et al. Quality of life and efficacy of nebivolol in an open-label study in hypertensive patients. The QoLaN study. Blood Press 2009;18:5-14
89. Mason RP, Kalinowski L, Jacob RF, et al. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of black Americans. Circulation 2005;112:3795-801 (Pubitemid 43739521)